



Showcasing research from Professor Robert Tampé's laboratory, Institute of Biochemistry, Goethe University Frankfurt, Germany, in collaboration with Professor Alexander Deiters, Department of Chemistry, University of Pittsburgh, PA, USA.

Light-guided intrabodies for on-demand *in situ* target recognition in human cells

Nanobodies are ideal probes for visualizing intracellular proteins. Inside living cells, unrestrained binding can cause interference with target function or localization. Here, we report a strategy to circumvent interference through the development of photo-conditional intrabodies. To regulate the interaction, we combine optochemical biology and genetic code expansion in stable cell lines. By equipping the paratope with photocaged amino acids, we control target binding with high spatiotemporal precision inside living cells. Due to the highly stable binding, light-guided intrabodies offer a versatile platform for comprehensive imaging and modulation of target proteins.

As featured in:



See Robert Tampé *et al.*,
Chem. Sci., 2021, **12**, 5787.

Cite this: *Chem. Sci.*, 2021, 12, 5787

All publication charges for this article have been paid for by the Royal Society of Chemistry

Received 7th March 2021
Accepted 22nd March 2021

DOI: 10.1039/d1sc01331a

rsc.li/chemical-science

Light-guided intrabodies for on-demand *in situ* target recognition in human cells†

Eike F. Joest,¹ Christian Winter,¹ Joshua S. Wesalo,¹ Alexander Deiters² and Robert Tampé^{1*}

Due to their high stability and specificity in living cells, fluorescently labeled nanobodies are perfect probes for visualizing intracellular targets at an endogenous level. However, intrabodies bind unrestrainedly and hence may interfere with the target protein function. Here, we report a strategy to prevent premature binding through the development of photo-conditional intrabodies. Using genetic code expansion, we introduce photocaged amino acids within the nanobody-binding interface, which, after photo-activation, show instantaneous binding of target proteins with high spatiotemporal precision inside living cells. Due to the highly stable binding, light-guided intrabodies offer a versatile platform for downstream imaging and regulation of target proteins.

Introduction

Nanobodies or V_HHs are single-domain binders derived from heavy chain-only antibodies of camelid or nurse shark species.^{1–3} These minimal antigen-binding fragments of 12 to 15 kDa are associated with nanomolar to subnanomolar affinity combined with high chemical and thermal stability.^{4,5} They quickly evolved into versatile tools for a broad spectrum of technologies, especially for imaging inside living cells.^{6–12} For fluorescent labeling, the nanobodies are typically coupled to organic dyes or fused to auto-fluorescent proteins, named chromobodies.¹⁴ For intracellular live-cell imaging, the nanobodies can be delivered by emerging technologies, such as cell squeezing, or are recombinantly expressed by transient transfection, termed intrabodies.^{6,14,15} Although the latter requires minimal efforts, the unbalanced level of unbound nanobodies leads to blurred signal-to-background ratios. Furthermore, it remains unclear whether the uncontrolled binding of nanobodies interferes with the function, assembly, and subcellular dynamics of intracellular target proteins before the actual analysis.¹⁶ To surpass possible artifacts derived from premature binding, a major advancement would be to control intrabody binding by light in living mammalian cells.

Nanobodies are also powerful tools for the modulation of target proteins. Their binding can directly influence target protein function or guide other proteins that offer control. Hence, a photo-conditional intrabody is a versatile platform for

in vivo regulation of target proteins. Here, we established stable human cell lines allowing synthesis of photo-conditional intrabodies. To this end, we expanded the genetic code of mammalian cells to incorporate amino acids equipped with a bulky photocage in the epitope-binding site.^{17,18} Genes coding for amber-suppressed intrabodies C-terminally fused to mCherry were site-specifically inserted into the genome of human cells using a recombinase system.¹⁹ Optimized amber codon suppression evoked the site-specific incorporation of photocaged amino acids and hence enabled intrabody expression. We traced the fluorescent intrabodies by flow cytometry or confocal laser-scanning microscopy (CLSM). On demand, we controlled the intrabody binding to its target in single cells. Immediately after a short pulse of light, we observed a complete subcellular reorganization of the intrabody towards the cognate target protein. Furthermore, fine-tuning of the exposed area and the exposure time enabled pulse-chase labeling. Our spatiotemporally controlled intrabody labeling prevents potential artifacts caused by constitutively active binding and hence offers advanced real-time studies of physiologically unrestricted target proteins.

Results and discussion

Light-guided intrabodies by genetic code expansion

As a proof of principle, we selected the well-described GFP-binding nanobody and recombinantly fused it to the red-fluorescent protein mCherry (Nb^{mCherry}).^{4,13} Based on the dimer crystal structure,¹³ we identified several amino acids within the epitope-binding region that could be exchanged towards a photocaged analog to block binding. Based on its crucial location, we selected tyrosine at position 37 (Tyr37) for amber suppression (Fig. 1A). For photo-caging of Tyr37, we used

¹Institute of Biochemistry, Biocenter, Goethe University Frankfurt, Max-von-Laue-Str. 9, 60438 Frankfurt, Germany. E-mail: tamp@em.uni-frankfurt.de

²Department of Chemistry, University of Pittsburgh, 219 Parkman Avenue, Pittsburgh, Pennsylvania 15260, USA

† Electronic supplementary information (ESI) available. See DOI: 10.1039/d1sc01331a






Fig. 1 On-demand tracing of intracellular targets by photo-activatable intrabodies. (A) The X-ray structure of the nanobody-GFP complex (pdb: 3K1K)¹³ reveals Tyr37 as a key residue in the binding region to GFP (turquoise). Nanobody, magenta. (B) Tyr37 is replaced by *ortho*-nitrobenzyl- or nitropiperonyl-caged tyrosines (ONBY or NPY, respectively). (C) Schematic illustration of stable cell line generation for expression of photo-activated intrabodies by genetic code expansion. Mammalian cells are co-transfected with plasmids encoding the recombinase and either wild-type (WT-Nb^{mCherry}) or amber-containing nanobodies (Amb-Nb^{mCherry}).

either *ortho*-nitrobenzyl-caged tyrosine (ONBY) or the novel nitropiperonyl-caged tyrosine (NPY) with improved light-activation properties (Fig. 1B).^{20,21} We used an optimized pyrrolysyl-tRNA synthetase (NPYRS)/tRNA pair²¹ for site-specific incorporation.

To prevent multiple transfections, we reasoned that it would be beneficial to stably integrate the nanobody constructs into the cellular genome. Thus, we used the Flp-InTM T-REXTM recombinase system and integrated the wild-type (WT-Nb^{mCherry}) and amber-containing (Amb-Nb^{mCherry}) constructs in HeLa cells.¹⁹ The integrated tetracycline inducible promoter allowed tight regulation of the intrabody expression (Fig. 1C).

Expression of intrabodies by stable cell lines

First, we analyzed the expression of WT-Nb^{mCherry} or Amb-Nb^{mCherry} in the stable cell lines by using the C-terminally fused mCherry as a reporter. After tetracycline induction, WT-Nb^{mCherry} was expressed at high levels as monitored by flow cytometry (Fig. 2A and B; ESI Fig. 1 and 2[†]). Live-cell CLSM imaging visualized fluorescent nanobody localization in the cytosol (Fig. 2A and C; ESI Fig. 3[†]). For the amber-suppressed Amb-Nb^{mCherry}, we established monoclonal cell lines based on the strongest mCherry signal referenced to cells cultured in the absence of the caged tyrosine. We combined tetracycline induction (0.1 $\mu\text{g ml}^{-1}$) with transfection of the NPYRS/tRNA plasmid and added the photocaged amino acid (0.25 mM) 4–6 h later to the media. The expression of Amb-Nb^{mCherry} in the established monoclonal cell line was further examined by flow cytometry. In contrast to untreated cells or the non-transduced

cell line, a strong mCherry signal of Amb-Nb^{mCherry}-positive cells was only observed under amber suppression conditions with either ONBY or NPY (Fig. 2D–F; ESI Fig. 1 and 4[†]). Strong fluorescence with equal cytosolic distribution of Amb-Nb^{mCherry} was visualized by live-cell CLSM imaging in the presence of ONBY or NPY (Fig. 2G; ESI Fig. 5[†]), confirming the incorporation of caged tyrosine at the amber codon. In the absence of the photocaged tyrosines or NPYRS/tRNA, the premature amber stop codon aborted the translation of full-length Amb-Nb^{mCherry}.

Next, we examined the intrabody properties by monitoring specific binding to different GFP-tagged target proteins. We transfected plasmids encoding the nuclear envelope protein LaminA, which was N-terminally tagged with mEGFP (mEGFP-LaminA), or the histone H2B, which was C-terminally tagged with EGFP (H2B^{EGFP}) (Fig. 2A and D).^{22,23} After tetracycline induction, WT-Nb^{mCherry}-positive cells showed the expected colocalization of GFP and mCherry fluorescence. It is worth mentioning that the amber suppression components did not affect the binding of the wildtype intrabody and hence the colocalization of GFP and mCherry (Fig. 2C; ESI Fig. 6 and 7[†]).

We subsequently analyzed binding in Amb-Nb^{mCherry}-positive HeLa cells. After transient transfection of the target genes, we did not record a colocalization of the Amb-Nb^{mCherry} with the two GFP-tagged targets under amber suppression conditions, demonstrating that both photocages, ONBY and NPY, block constitutive intrabody binding (Fig. 2G; ESI Fig. 8–10[†]). However, after exposing cells to a short 405 nm light pulse to induce photo-cleavage of the caging group, we observed an instantaneous subcellular reorganization of Amb-Nb^{mCherry}. Corroborated by colocalization in living cells, the intrabody






Fig. 2 Expression of photo-activatable intrabodies by stable cell lines. (A) Wild-type intrabody $^{WT}Nb^{mCherry}$ is expressed after tetracycline induction. For intracellular binding analysis, a plasmid encoding a GFP-tagged target is transiently transfected; tet, tetracycline. (B) $^{WT}Nb^{mCherry}$ expression analyzed by flow cytometry without (–) or with (+) tetracycline induction. (C) Live-cell imaging showing expression of $^{WT}Nb^{mCherry}$ and binding of $^{mEGFP}LaminA$ (relative PMT gain settings from the image acquisition in grey). (D) Intrabody $^{Amb}Nb^{mCherry}$ expression by amber suppression with photocaged tyrosines. $^{Amb}Nb^{mCherry}$ -positive cells are transiently transfected with plasmids encoding the optimized NPYRS/tRNA pair and a target protein, respectively. After transfection, $^{Amb}Nb^{mCherry}$ expression was induced when cells were supplied with photocaged tyrosines. (E) Expression of $^{WT}Nb^{mCherry}$ and $^{Amb}Nb^{mCherry}$ monitored by flow cytometry. $^{WT}Nb^{mCherry}$ expression was tetracycline-induced and $^{Amb}Nb^{mCherry}$ was expressed using amber suppression conditions. Cell counts were normalized to mode ($n = 3$). (F) Amber suppression conditions enabling $^{Amb}Nb^{mCherry}$ expression with photocaged amino acids. Mean fluorescence of monoclonal $^{Amb}Nb^{mCherry}$ -positive cells analyzed by flow cytometry ($n = 3$). Normalized to expression with amber suppression conditions in the presence of NPY. (G) Live-cell imaging of $^{Amb}Nb^{mCherry}$ revealing blocking of binding to $^{GFP}LaminA$ through incorporation of photocaged ONBY or NPY at Tyr37. In (F) and (G): (–) no supplements, (+) transient transfection of NPYRS/tRNA, (++) transient transfection of NPYRS/tRNA and tetracycline induction. In (C) and (G): scale bar = 10 μm .

bound either to $^{mEGFP}LaminA$ at the nuclear envelope or to histone H2B EGFP in the nucleus, using either ONBY or NPY (Fig. 3A and B; ESI Fig. 9 and 10 \dagger). Furthermore, we repeated the experiment with $^{WT}Nb^{mCherry}$ -expressing cells to exclude phototoxic artifacts.²⁴ The location and constitutive binding of $^{WT}Nb^{mCherry}$ remained unaffected, especially in case of cells with saturating nanobody amounts (ESI Fig. 11 and 12 \dagger). Finally, we analyzed photo-activated nanobody-EGFP binding in cell lysates. By co-immunoprecipitation, we captured $^{WT}Nb^{mCherry}$ and associated EGFP from the respective lysates. Subsequently, specific binding in cell lysates was quantified using EGFP fluorescence. After photo-activation, $^{Amb}Nb^{mCherry}$ resembled the EGFP enrichment obtained by the same amount of $^{WT}Nb^{mCherry}$ (ESI Fig. 13 \dagger). The results demonstrated the efficiency and specificity of light-triggered restoration of epitope recognition.

Photo-activation with high spatiotemporal precision

We next focused on the intracellular activation of $^{Amb}Nb^{mCherry}$ by light, visualizing the decoration of $^{mEGFP}LaminA$ as a target. For statistical analysis of the induced binding, we quantified the increase in colocalization after illumination. Therefore, we observed strong predominance of cells containing high amounts of target protein (ESI Fig. 14 \dagger). To monitor target binding in 3D, we recorded high-resolution z-stacks before and after photo-activation. Before photo-activation, we observed an equally distributed cytosolic fluorescence of $^{Amb}Nb^{mCherry}$ and, immediately after illumination, a background-free colocalization by intrabody binding (Fig. 3C). Full photo-activation was achieved within the first few minutes of illumination. Apart from the temporal resolution, we also investigated the spatial precision of photo-activation by step-wise exposing cells in close






Fig. 3 Photo-activation of intrabodies with high spatiotemporal precision. (A) Light exposure unleashes the intrabody and hence allows instant binding to the target protein. (B) Live-cell imaging and photo-activation of $\text{AmbNb}^{\text{mCherry}}$. After photo-activation, $\text{AmbNb}^{\text{mCherry}}$ and target protein colocalization was observed. Corresponding line scans highlight intrabody binding. (C) 3D imaging revealing almost background-free target binding of $\text{AmbNb}^{\text{mCherry}}$ after illumination. (D) Single-cell intrabody photo-activation with high local precision. (E) Fine-tuned $\text{AmbNb}^{\text{mCherry}}$ photo-activation by local energy dosage. In (D) and (E), yellow boxes indicate the light-exposed area. Maximum light exposure corresponds to a bleaching function with 250 iterations and 50 cycles using a 405 nm diode laser ($4.5 \text{ mW } \mu\text{m}^{-2}$). The whole region of interest (ROI) or the indicated rectangular selection was illuminated, respectively. Cells were supplemented with NPY.

proximity. We analyzed $\text{AmbNb}^{\text{mCherry}}$ -positive cells, treated with NPY and expressing $\text{mEGFP}^{\text{LaminaA}}$, that were within less than $5 \mu\text{m}$ distance. We observed specific activation of individual cells and no target protein engagement in adjacent cells (Fig. 3D). For improved control of binding within an individual $\text{AmbNb}^{\text{mCherry}}$ -positive cell, we carefully increased the light exposure and recorded the reorganization immediately afterwards. Nanobody binding, monitored by colocalization, strictly correlated with light exposure, offering complete or graded levels of activation (ESI Fig. 15 and 16†). The improved photo-activation properties of NPY allowed saturating activation at 20–40% of light exposure as compared to ONBY (ESI Fig. 17†). Finally, for fine-tuned activation, we only exposed a defined small part of NPY

$\text{AmbNb}^{\text{mCherry}}$ -positive cells with distinct exposure times. We achieved stringent control of activation and hence intrabody binding, as evidenced by a progressive increase of colocalization (Fig. 3E, ESI Fig. 15†). In summary, these results demonstrate fast photo-controlled nanobody binding and high spatiotemporal precision by using an optimized cellular amber suppression system.

Conclusions

In this study, we generated stable mammalian cell lines for expression of photo-conditional intrabodies by genetic code expansion. We site-specifically incorporated photocages within



the epitope-binding site of the α -GFP nanobody at position Tyr37.^{13,20,21} While our studies were ongoing, this design approach was further validated through the incorporation of caged tyrosines into a nanobody expressed in *E. coli*.²⁵ In our stable mammalian cell line, we monitored amber suppression by flow cytometry and CLSM using a fluorescent reporter. We revealed that incorporation of the photocaged tyrosines ONBY and NPY prevented constitutive binding in the amber-suppressed ^{Amb}Nb^{mCherry}. Cleavage of the photocages by light restored the epitope-binding site and allowed instantaneous target binding. Within a few minutes of illumination, a complete reorganization of the intrabody by colocalization to the target protein was observed, demonstrating efficient photo-activation. Fine-tuning the exposed area and exposure time finally allowed strict control of intrabody binding.

Previous studies have reported on nanobody–photoreceptor hybrids. The combination of optogenetics and nanobodies with fast dissociation rates facilitated reversible intracellular binding.^{26–28} Here, we demonstrate a fundamentally different approach using (opto)chemical biology to control a nanobody with kinetically stable, long-term binding.^{4,13} Both approaches offer intrinsic advantages. Optogenetic control allows reversible activation after comprehensive bioengineering, while optochemical activation by photo-deprotection can be rationally designed based on structural information and restores the native protein. Thus, these two methods form a complementary toolbox to control intrabodies with light. The focus of our study is on the on-demand intrabody binding by genetic code expansion. The controlled interaction circumvents potential interference with the target protein caused by constitutive binding.

We established a stable cell line for expression of the intrabody ^{WT}Nb^{mCherry}. In future studies, a combination of both cell lines can be used to identify target interference caused by the constitutive binding of ^{WT}Nb^{mCherry}. In addition, we used an intrabody with kinetically stable target binding, which facilitated comprehensive imaging experiments. Stable binding forms the basis for potential target protein modulation.²⁹ To visualize intrabody expression and binding, we used a C-terminally fused mCherry. Alternatively, the fluorescent reporter of the intrabody could be replaced by a proteasomal degradational signal.^{29–31} This will allow on-demand post-translational target knock-downs in defined regions. Additionally, several other photocaged amino acids with optimized PylRS/tRNA pairs and nanobodies are available. Combined with our general approach, photo-activatable nanobodies for various functions can be generated. Particularly, the implementation of advanced photocages enables deep tissue activation and intracellular labeling lithography.^{32–36} Moreover, new CRISPR-Cas12a-guided methods allow the versatile tagging of endogenous proteins with small peptide tags, which can be detected by photo-activatable intracellular nanobodies.³⁷

Genetic code expansion in stable cell lines harboring a respective PylRS/tRNA pair and an amber-codon construct is challenging and not always beneficial.³⁸ We chose a hybrid approach by stably integrating the amber-modified target gene using a recombinase and transiently transfecting a plasmid

encoding the NPYRS/tRNA pair. The combination of transient transfection and tetracycline-induction of a stable cell line allows parallel expression of several different proteins. Therefore, we achieved intrabody synthesis with non-natural tyrosines by amber suppression using the optimized PylRS/tRNA pair, and simultaneously expressed an additional target protein. The parallel expression of different proteins and the incorporation of photo-conditional tyrosines offer further powerful applications in basic and applied research. Post-translational modification of tyrosine residues plays a major role in cellular biochemistry.³⁹ Due to the easy transferability, our approach can serve as a blueprint to control signaling proteins in complex networks.⁴⁰ In particular, in connection with receptor tyrosine kinases, our stable cell line concept allows modulation of *trans*-phosphorylation and the resulting signaling.^{41–44} Thus, the parallel expression of other genes will pave the way for comprehensive analysis of downstream processes.

In summary, genetic code expansion facilitates the precise control of intrabody binding by light. The conditional interaction circumvents potential artifacts of constitutively binding nanobodies and can guide nanobody-mediated target protein modulation. In general, our stable cell line approach is a versatile proof-of-concept for analyzing proteins in complex pathways *via* photo-caged tyrosine residues. We are convinced that, together with other extracellular photo-activatable binders, these new experimental possibilities will enlarge and improve the broad spectrum of nanobody applications.^{25,45,46}

Experimental

Molecular biology

Enzymes for molecular biology were used according to the manufacturers' protocols. DNA amplification was performed with the Phusion™ High-Fidelity DNA Polymerase. For ligation, T4 DNA ligase was applied. The α -GFP^{mCherry} (ref. 13) construct was cloned into a pcDNA3.1(+) plasmid by PCR.⁶ The amber mutation Tyr37TAG was introduced by site-directed mutagenesis using the following primers: fwd 5'-AGC ATG CGT TGG TAG CGT CAG GCA CCG-3', rev 5'-CGG TGC CTG ACG CTA CCA ACG CAT GCT-3' (mutation in bold). The target plasmid containing the ^{mEGFP}LaminaA construct was generated by site-directed mutagenesis and PCR as previously described.^{22,47} H2B^{EGFP} in pEGFP-N1 was a gift from Geoffrey Wahl (Addgene #11680).²³ The plasmid encoding the optimized NPYRS/4xPylT pair was previously generated.²¹ The pyrrolysine tRNA synthetase (PylRS) of *Methanosarcina barkeri* was modified with the mutations L270F, L274M, N311G, and C313G.²¹ For the generation of the stable cell line by the Flp-In™ T-REX™ system, the amber-free and amber-containing α -GFP^{mCherry} constructs were PCR amplified and cloned into the pcDNA5/FRT/TO plasmid (Thermo Fisher Scientific). Therefore, a primer pair introducing an upstream HindIII restriction site and a downstream NotI restriction site was utilized: HindIII fwd 5'-GCG CGC AAG CTT ACC ATG CAG GTT CAG CTG GTT GAA AGC GGT GGT G-3', NotI rev 5'-GCG CGC GCG GCC GCC TAC TTG TAC AGC TCG TCC ATG CCG CCG-3' (restriction sites are underlined).



Cell culture and generation of a stable cell line

The generation of the stable HeLa cell line was performed by co-transfection of the respective pcDNA5/FRT/TO constructs, the pOG44 Flp-recombinase expression vector (Thermo Fisher Scientific), and blasticidin (Gibco) and hygromycin (Invitrogen) selection, following the manufacturer's protocol. Transient transfection by Lipofectamine 2000 (Life Technologies) was performed according to the manufacturer's guidelines. Unmodified T-REX™-HeLa cells (Thermo Fisher Scientific) were maintained in DMEM medium containing 4.5 g L⁻¹ glucose (Gibco), supplemented with 10% (v/v) FCS tetracycline-negative (BIO&SELL) in T75 cell culture flasks (Greiner). After recombinase reaction, the medium was supplemented with 2 µg ml⁻¹ blasticidin (Gibco) and 100 µg ml⁻¹ hygromycin (Invitrogen) according to the manufacturer's instructions. Cell passage was performed by using PBS (Sigma-Aldrich) and 0.05% trypsin-EDTA (Gibco) every 2–3 days. Cells were cultivated in a tissue culture incubator at 37 °C and humidified with 5% CO₂. Following established guidelines, mycoplasma contamination tests were regularly carried out.⁴⁸ Stable monoclonal cell lines were established by flow cytometry cell sorting based on highest fluorescence (see below). For live-cell imaging, 2.5 × 10⁴ cells were seeded per glass-bottom 8-well imaging slide (Sarstedt). For flow cytometry, 5 × 10⁵ cells were seeded per 6-well (Greiner), harvested using PBS (Sigma-Aldrich) and 0.05% trypsin-EDTA (Gibco), washed once with normal selection medium and once with PBS (Sigma-Aldrich).

Intrabody gene expression and genetic code expansion

The expression cassette of the Flp-In™ T-REX™ expression cell lines contained a tetracycline inducible promoter. For induction of gene expression, we followed the manufacturer's instruction and used 0.1 µg ml⁻¹ tetracycline. For genetic code expansion by amber suppression in AmbNb^{mCherry}-positive cells, transient transfection of the NPYRS/4xPylT encoding plasmid was followed 4–6 h later by exchanging the medium with amber suppression medium (DMEM, 4.5 g L⁻¹ glucose (Gibco), 10% (v/v) FCS tetracycline-negative (BIO&SELL), 0.1 µg ml⁻¹ tetracycline, and 0.25 mM ONBY (Santa Cruz Biotechnology) or NPY). NPY was synthesized as previously described.²¹ Transient transfection or exposure to unnatural amino acids is stressful for cells. For optimal culture conditions, we decided to use an established approach for mammalian cells with 4–6 h solely for transfection.^{49,50} Unnatural amino acids were dissolved, sterile-filtered and stored in 100 mM NaOH. The compounds were used at the limit of solubility. We recommend preparing a stock solution of hardly soluble NPY by end-over-end rotation for 2 h at room temperature. After supplementing DMEM with unnatural amino acids in NaOH, the pH was neutralized by the same volume of 100 mM sterile filtered HCl. Cells were cultivated in the corresponding medium for 24–48 h before experimental analysis.

CLSM live-cell imaging and photo-activation

For live-cell imaging of WTNb^{mCherry}, cells were transiently transfected with mEGFP^{LaminA} or H2B^{EGFP}-encoding plasmids.

For AmbNb^{mCherry}-positive cells, the NPYRS/4xPylT plasmid was transiently co-transfected (1 : 1 plasmid ratio) with the corresponding target plasmid, prior to addition of amber suppression medium. For transfection, Lipofectamine 2000 (Life Technologies) was used according to the manufacturer's instructions. Images were recorded 24–48 h after medium exchange or induction, respectively. For live-cell imaging, cells were covered by Ringer solution (145 mM NaCl, 5 mM KCl, 2 mM CaCl₂, 1 mM MgCl₂, 10 mM HEPES, 10 mM glucose, pH 7.4), incubated at 37 °C and humidified with 5% CO₂. Imaging was performed by using a confocal laser-scanning microscope, Zeiss LSM 880 (Carl Zeiss Jena GmbH, Germany), combined with a Plan Aplanachromat 63x/1.4 oil DIC objective. In order to avoid crosstalk, sequential imaging was used. EGFP excitation was achieved using a 488 nm argon laser and mCherry excitation using a 543 nm helium–neon laser. For EGFP imaging, the gain was adjusted to the level of transient transfection. mCherry was recorded using similar settings for each shown experiment, and relative alterations were indicated. Photo-activation was performed by using a bleaching function with 250 iterations, 50 cycles and a 405 nm diode laser (4.5 mW µm⁻²) for the whole ROI or with a rectangular selection, if indicated. For 3D rendering of z stacks, the ZenBlack (Carl Zeiss Jena GmbH, Germany) surface function was applied. Images were analyzed using ZenBlue (Carl Zeiss Jena GmbH, Germany), Excel (Microsoft) and Fiji.⁵¹

Flow cytometry

For monoclonal sorting, AmbNb^{mCherry}-positive cells were transiently transfected with the NPYRS/4xPylT-encoding plasmid, incubated in media supplemented with tetracycline and NPY, and analyzed 48 h after transfection. Cells with highest fluorescence were individually collected in 96-well plates (Greiner) and expanded to culture size. For expression analysis 48 h after transient transfection of the NPYRS/4xPylT-encoding plasmid, the fluorescence of AmbNb^{mCherry}- or WTNb^{mCherry}-positive mono- and polyclonal cells was recorded in biological triplicate by flow cytometry (FACSMelody, BD Biosciences). mCherry fluorescence was obtained using the 561 nm laser line with a 613/18/LP605/10 filter set. Standard gates for doublet discrimination were applied to all samples. FACS data were evaluated with FlowJo 10.6.2 (BD), with the cell count normalized to the mode using the mCherry fluorescence area, or plotted in OriginPro 2020 (OriginLab), reporting the mean mCherry fluorescence area.

EGFP-binding assay

To obtain high amounts of WT/AmbNb^{mCherry} containing lysates, 5 × 10⁵ HeLa cells were seeded per 6-well (Greiner). Cells were cultured in DMEM medium containing 4.5 g L⁻¹ glucose (Gibco), 10% (v/v) FCS tetracycline-negative (BIO&SELL), 2 µg ml⁻¹ blasticidin (Gibco), and 100 µg ml⁻¹ hygromycin (Invitrogen). On the following day, the medium was renewed and AmbNb^{mCherry} cells transfected with the NPYRS/4xPylT encoding plasmid using Lipofectamine 2000 (Life Technologies). For increased comparability, WTNb^{mCherry} cells were also transfected



with the NPYRS/4xPylT plasmid. 4–6 h after transfection, the medium was renewed and supplemented with $0.1 \mu\text{g ml}^{-1}$ tetracycline for induction. To evoke amber suppression, 0.25 mM ONBY (final) was added to the medium of $\text{AmbNb}^{\text{mCherry}}$ -expressing cells. After 24 h, cells were harvested using PBS (Sigma-Aldrich) and 0.05% trypsin–EDTA (Gibco), washed once with normal selection medium and once with PBS (Sigma-Aldrich). Cells were lysed in Pierce RIPA buffer (Thermo Fisher Scientific) containing 1% (v/v) Benzonase (Merck Millipore) and 1% (v/v) Protease-Inhibitor Mix HP (Serva). For lysis, cells of three individual 6-well plates were pooled and incubated in $300 \mu\text{l}$ lysis buffer for 1 h at RT with end-over-end rotation. Afterwards, samples were centrifuged at $21\,000g$ for 30 min at 4°C and the supernatant was collected. Protein concentration of the obtained lysates was determined by using the Pierce Detergent Compatible Bradford Assay Kit (Thermo Fisher Scientific). For the *in vitro* GFP-binding assay, lysates of three individual preparations were pooled. For $\text{AmbNb}^{\text{mCherry}}$ photo-activation, the lysate was exposed to UV light (three times for 3 min with 365 nm at 100 mW , ThorLabs DC 2200 M365L2 $\lambda = 365 \text{ nm}$ UV lamp with attached collimator SM2F32-A). Tyrosine deprotection was validated by mass spectrometry (ESI Fig. 18†). To capture $\text{WT/AmbNb}^{\text{mCherry}}$ from the lysates, RFP-Trap Agarose (Chromotek) was used according to the manufacturer's protocol. In total, $0.5 \text{ mg WT/AmbNb}^{\text{mCherry}}$ - or $1.0 \text{ mg AmbNb}^{\text{mCherry}}$ -expressing cell lysate was mixed with $25 \mu\text{l}$ of agarose bead slurry. Samples were filled to $500 \mu\text{l}$ with dilution buffer ($10 \text{ mM Tris/Cl pH } 7.5$, 150 mM NaCl , 0.5 mM EDTA) and EGFP (120 nM final) was added. After 1 h end-over-end rotation at 4°C , beads were washed three times using washing buffer ($10 \text{ mM Tris/Cl pH } 7.5$, 150 mM NaCl , 0.05% Tween 20, 0.5 mM EDTA). Beads were resuspended in 1 ml washing buffer, and EGFP fluorescence was recorded at $\lambda_{\text{ex/em}} 488/509 \text{ nm}$. As controls, lysates of untransfected monoclonal $\text{AmbNb}^{\text{mCherry}}$ cells cultured in normal selection medium were used. To prevent bead sedimentation during analysis, samples were gently resuspended and measured immediately in triplicate. To normalize the recorded fluorescence intensities, the ratios of captured $\text{WT/AmbNb}^{\text{mCherry}}$ and $\text{AmbNb}^{\text{mCherry}}$ were determined by immunoblotting against mCherry.

Immunoblotting

After quantification of the EGFP binding by fluorescence, beads were boiled at 95°C for 10 min in $15 \mu\text{l}$ $5\times$ SDS loading dye (0.02% (w/v) bromophenol blue, 30% (v/v) glycerol, 10% (w/v) SDS, 250 mM Tris-HCl , 250 mM DTT , $\text{pH } 6.8$). Samples were separated by 12% Tris–glycine SDS-PAGE. After electrophoresis, the gel was blotted semi-dry on nitrocellulose membrane. As transfer buffer, 25 mM Tris , 100 mM glycine , 0.1% (w/v) SDS and 20% (v/v) methanol was used. The membrane was blocked for 1 h in 5% (w/v) nonfat milk powder containing Tris-buffered saline with TWEEN 20 (TBS-T, $\text{pH } 7.4$). Blocking was followed by three consecutive washing steps with TBS-T. Afterwards, the membrane was incubated with monoclonal primary anti-mCherry antibody (Abcam, EPR20579) derived from rabbit $1 : 1000$ in blocking buffer at 8°C overnight. Unbound primary

antibody was removed in three washing steps with TBS-T. As the secondary antibody, anti-Rabbit IgG antibody (H + L) HRP conjugate produced in goat (Sigma-Aldrich) was used $1 : 10\,000$ in TBS-T incubated for 1 h. Three TBS-T washing steps followed the incubation with the secondary antibody. For chemiluminescent detection *via* the HRP, an ECL solution (Clarity Western ECL Substrate, Bio-Rad) was applied, and visualized by a Fusion FX imaging system (Vilber).

Mass spectrometry

ONBY and NPY, respectively, were analyzed using a Waters BioAccord system running UNIFY 1.9.4. Samples were separated on an Acquity BEH C18 column ($1.7 \mu\text{m}$, $2.1 \text{ mm} \times 50 \text{ mm}$). Identity was verified for NPY (M_{calc} : 360.0958 Da , M_{obs} : 360.0946 Da [-3.2 ppm]) and ONBY (M_{calc} : 316.1059 Da , M_{obs} : 316.1050 Da [-2.8 ppm]) using a cone voltage of 30 V and capillary voltage of 0.8 kV in positive polarity. Photo-cleavage was performed in neutral pH PBS at $100 \mu\text{M}$ sample concentration. Samples were irradiated with a ThorLabs DC 2200 (M365L2) $\lambda = 365 \text{ nm}$ UV lamp with an attached collimator (SM2F32-A) at 100 mW for different timeframes. For NPY and ONBY, the peak height at 214 nm was normalized to the uncleaved sample and fitted with an exponential decay function using OriginPro 2020. For uncaged tyrosine, the ESI-MS detector response was used instead.

Author contributions

E. J. generated the stable cell lines and performed the CLSM experiments. FACS experiments were carried out by C. W. and E. J. Samples for the *in vitro* GFP-binding assay were prepared by E. J. and analyzed by E. J. and C. W. C. W. performed the mass spectrometric analyses. E. J., C. W. and R. T. carried out the data analysis. Photocaged amino acids were synthesized by J. S. W., supervised by A. D. E. J. and R. T. wrote the manuscript with contributions from all authors. R. T. conceived and supervised the project.

Conflicts of interest

The authors declare no conflicts of interest.

Acknowledgements

We thank Samuel Seidl for preliminary experiments, Katharina Lindt for cell culture support, and Dr Kathrin Lang (TU Munich), Dr Ralph Wieneke, Andrea Pott, Inga Nold, Jamina Brunnberg, Stefan Bruchert, Philipp Höllthaler, and Tim Diederichs for helpful discussions. We further thank Stefan Frühschulz for providing the EGFP. The German Research Foundation (GRK 1986, TA157/12-1, and SFB 807 to R.T.), the Volkswagen Foundation (Az. 96 496 to R.T.), the National Science Foundation (CHE-1904972 to A. D.), and the National Institute of Health (R01GM132565 to A.D.) supported this work.



References

- 1 C. Hamers-Casterman, T. Atarhouch, S. Muyldermans, G. Robinson, C. Hammers, E. B. Songa, N. Bendahman and R. Hammers, *Nature*, 1993, **363**, 446–448.
- 2 A. S. Greenberg, D. Avila, M. Hughes, A. Hughes, E. C. McKinney and M. F. Flajnik, *Nature*, 1995, **374**, 168–173.
- 3 L. Riechmann and S. Muyldermans, *J. Immunol. Methods*, 1999, **231**, 25–38.
- 4 M. H. Kubala, O. Kovtun, K. Alexandrov and B. M. Collins, *Protein Sci.*, 2010, **19**, 2389–2401.
- 5 P. Kunz, K. Zinner, N. Mücke, T. Bartoschik, S. Muyldermans and J. D. Hoheisel, *Sci. Rep.*, 2018, **8**, 7934.
- 6 A. Klein, S. Hank, A. Raulf, E. F. Joest, F. Tissen, M. Heilemann, R. Wieneke and R. Tampé, *Chem. Sci.*, 2018, **9**, 7835–7842.
- 7 H. Götzke, M. Kilisch, M. Martínez-Carranza, S. Sograte-Idrissi, A. Rajavel, T. Schlichthaerle, N. Engels, R. Jungmann, P. Stenmark, F. Opazo and S. Frey, *Nat. Commun.*, 2019, **10**, 4403.
- 8 J. Helma, M. C. Cardoso, S. Muyldermans and H. Leonhardt, *J. Cell Biol.*, 2015, **209**, 633–644.
- 9 J. Ries, C. Kaplan, E. Platonova, H. Eghlidi and H. Ewers, *Nat. Methods*, 2012, **9**, 582–584.
- 10 D. Virant, B. Traenkle, J. Maier, P. D. Kaiser, M. Bodenhöfer, C. Schmees, I. Vojnovic, B. Pisak-Lukáts, U. Endesfelder and U. Rothbauer, *Nat. Commun.*, 2018, **9**, 930.
- 11 J. Huo, A. Le Bas, R. R. Ruza, H. M. E. Duyvesteyn, H. Mikolajek, T. Malinauskas, T. K. Tan, P. Rijal, M. Dumoux, P. N. Ward, J. Ren, D. Zhou, P. J. Harrison, M. Weckener, D. K. Clare, V. K. Vogirala, J. Radecke, L. Moynié, Y. Zhao, J. Gilbert-Jaramillo, M. L. Knight, J. A. Tree, K. R. Buttigieg, N. Coombes, M. J. Elmore, M. W. Carroll, L. Carrique, P. N. M. Shah, W. James, A. R. Townsend, D. I. Stuart, R. J. Owens and J. H. Naismith, *Nat. Struct. Mol. Biol.*, 2020, **27**, 846–854.
- 12 E. A. Della Pia and K. L. Martinez, *PLoS One*, 2015, **10**, e0124303.
- 13 A. Kirchhofer, J. Helma, K. Schmidthals, C. Frauer, S. Cui, A. Karcher, M. Pellis, S. Muyldermans, C. Casas-Delucchi, M. C. Cardoso, H. Leonhardt, K. Hopfner and U. Rothbauer, *Nat. Struct. Mol. Biol.*, 2010, **17**, 133–138.
- 14 U. Rothbauer, K. Zolghadr, S. Tillib, D. Nowak, L. Schermelleh, A. Gahl, N. Backmann, K. Conrath, S. Muyldermans, M. C. Cardoso and H. Leonhardt, *Nat. Methods*, 2006, **3**, 887–889.
- 15 A. L. J. Marschall, S. Dübel and T. Böldicke, *mAbs*, 2015, **7**, 1010–1035.
- 16 F. Schneider, T. Sych, C. Eggeling and E. Sezgin, *iScience*, 2021, **24**, 101891.
- 17 K. Lang and J. W. Chin, *Chem. Rev.*, 2014, **114**, 4764–4806.
- 18 N. Wu, A. Deiters, T. A. Cropp, D. King and P. G. Schultz, *J. Am. Chem. Soc.*, 2004, **126**, 14306–14307.
- 19 D. Gründemann, S. Harlfinger, S. Golz, A. Geerts, A. Lazar, R. Berkels, N. Jung, A. Rubbert and E. Schömig, *Proc. Natl. Acad. Sci. U. S. A.*, 2005, **102**, 5256–5261.
- 20 A. Deiters, D. Groff, Y. Ryu, J. Xie and P. G. Schultz, *Angew. Chem., Int. Ed.*, 2006, **45**, 2728–2731.
- 21 J. Luo, J. Torres-Kolbus, J. Liu and A. Deiters, *ChemBioChem*, 2017, **18**, 1442–1447.
- 22 K. Gatterdam, E. F. Joest, M. S. Dietz, M. Heilemann and R. Tampé, *Angew. Chem., Int. Ed.*, 2018, **57**, 5620–5625.
- 23 T. Kanda, K. F. Sullivan and G. M. Wahl, *Curr. Biol.*, 1998, **8**, 377–385.
- 24 J. Icha, M. Weber, J. C. Waters and C. Norden, *BioEssays*, 2017, **39**, 1700003.
- 25 B. Jedlitzke, Z. Yilmaz, W. Dörner and H. D. Mootz, *Angew. Chem., Int. Ed.*, 2020, **59**, 1506–1510.
- 26 T. A. Redchuk, M. M. Karasev, P. V. Verkhusha, S. K. Donnelly, M. Hülsemann, J. Virtanen, H. M. Moore, M. K. Vartiainen, L. Hodgson and V. V. Verkhusha, *Nat. Commun.*, 2020, **11**, 605.
- 27 D. Yu, H. Lee, J. Hong, H. Jung, Y. Jo, B. H. Oh, B. O. Park and W. D. Heo, *Nat. Methods*, 2019, **16**, 1095–1100.
- 28 A. A. Gil, C. Carrasco-López, L. Zhu, E. M. Zhao, P. T. Ravindran, M. Z. Wilson, A. G. Goglia, J. L. Avalos and J. E. Toettcher, *Nat. Commun.*, 2020, **11**, 4044.
- 29 E. Caussin, O. Kanca and M. Affolter, *Nat. Struct. Mol. Biol.*, 2012, **19**, 117–121.
- 30 A. Hermann, J. F. Liewald and A. Gottschalk, *Curr. Biol.*, 2015, **25**, R749–R750.
- 31 C. Renicke, D. Schuster, S. Usherenko, L. Essen and C. Taxis, *Chem. Biol.*, 2013, **20**, 619–626.
- 32 J. Luo, R. Uprety, Y. Naro, C. Chou, D. P. Nguyen, J. W. Chin and A. Deiters, *J. Am. Chem. Soc.*, 2014, **136**, 15551–15558.
- 33 C. A. Hammer, K. Falahati, A. Jakob, R. Klimek, I. Burghardt, A. Heckel and J. Wachtveitl, *J. Phys. Chem. Lett.*, 2018, **9**, 1448–1453.
- 34 R. R. Nani, A. P. Gorka, T. Nagaya, T. Yamamoto, J. Ivanic, H. Kobayashi and M. J. Schnermann, *ACS Cent. Sci.*, 2017, **3**, 329–337.
- 35 C. Aonbangkhen, H. Zhang, D. Z. Wu, M. A. Lampson and D. M. Chenoweth, *J. Am. Chem. Soc.*, 2018, **140**, 11926–11930.
- 36 T. A. Shell, J. R. Shell, Z. L. Rodgers and D. S. Lawrence, *Angew. Chem., Int. Ed.*, 2014, **53**, 875–878.
- 37 J. Fueller, K. Herbst, M. Meurer, K. Gubicza, B. Kurtulmus, J. D. Knopf, D. Kirrmaier, B. C. Buchmuller, G. Pereira, M. K. Lemberg and M. Knop, *J. Cell Biol.*, 2020, **219**, e201910210.
- 38 S. J. Elsässer, R. J. Ernst, O. S. Walker and J. W. Chin, *Nat. Methods*, 2016, **13**, 158–164.
- 39 M. D. Paul and K. Hristova, *Cytokine Growth Factor Rev.*, 2019, **49**, 23–31.
- 40 E. Arbely, J. Torres-Kolbus, A. Deiters and J. W. Chin, *J. Am. Chem. Soc.*, 2012, **134**, 11912–11915.
- 41 C. L. Neben, M. Lo, N. Jura and O. D. Klein, *Dev. Biol.*, 2019, **447**, 71–89.
- 42 J. Schlessinger, *Cold Spring Harbor Perspect. Biol.*, 2014, **6**, a008912.
- 43 M. A. Lemmon and J. Schlessinger, *Cell*, 2010, **141**, 1117–1134.
- 44 S. R. Hubbard and J. H. Till, *Annu. Rev. Biochem.*, 2000, **69**, 373–398.



- 45 H. Farrants, V. A. Gutzeit, A. Acosta-Ruiz, D. Trauner, K. Johnsson, J. Levitz and J. Broichhagen, *ACS Chem. Biol.*, 2018, **13**, 2682–2688.
- 46 T. Bridge, S. A. Shaikh, P. Thomas, J. Botta, P. J. McCormick and A. Sachdeva, *Angew. Chem., Int. Ed.*, 2019, **58**, 17986–17993.
- 47 A. Kollmannsperger, A. Sharei, A. Raulf, M. Heilemann, R. Langer, K. F. Jensen, R. Wieneke and R. Tampé, *Nat. Commun.*, 2016, **7**, 10372.
- 48 C. C. Uphoff and H. G. Drexler, *Curr. Protoc. Mol. Biol.*, 2014, **106**, 28.24.1–28.24.14.
- 49 C. Uttamapinant, J. D. Howe, K. Lang, V. Beránek, L. Davis, M. Mahesh, N. P. Barry and J. W. Chin, *J. Am. Chem. Soc.*, 2015, **137**, 4602–4605.
- 50 M. Cigler, T. A. Nguyen and K. Lang, in *Oxidative Folding of Proteins: Basic Principles, Cellular Regulation and Engineering*, The Royal Society of Chemistry, 2018, pp. 399–420.
- 51 J. Schindelin, I. Arganda-Carreras, E. Frise, V. Kaynig, M. Longair, T. Pietzsch, S. Preibisch, C. Rueden, S. Saalfeld, B. Schmid, J. Tinevez, D. J. White, V. Hartenstein, K. Eliceiri, P. Tomancak and A. Cardona, *Nat. Methods*, 2012, **9**, 676–682.

